We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA ISSUES WARNING LETTER TO ORTHOPEDIST IN DEVICE STUDY

FDA ISSUES WARNING LETTER TO ORTHOPEDIST IN DEVICE STUDY

May 23, 2006

An orthopedic surgeon in Tyler, Texas, received an FDA warning letter for violating rules that protect clinical trial participants in a device trial.

The agency cited clinical investigator Dennis Devinney for failing to obtain informed patient consent before surgically implanting an investigational medical device, which the FDA did not identify.

According to a website for the East Texas Medical Center's orthopedic institute, Devinney performs a procedure called reverse shoulder prosthesis as part of a research study at the site.

In its April 21 warning letter, the FDA claims that proper informed consent was not obtained for nine of Devinney's 19 study participants. Two patients received study-related procedures prior to consenting, and seven gave consent through a document that was not approved by an institutional review board (IRB), the agency said.

Devinney also enrolled patients who did not meet the study's inclusion criteria, the FDA said. Inspectors noted the inclusion of at least two subjects who did not qualify based on preoperative pain ratings. Additionally, baseline assessments were not documented for these subjects, the letter states.

As the study progressed, Devinney failed to report unanticipated adverse effects to the IRB, the agency claims. The letter states that, in one instance, a suture abscess was not immediately reported to the IRB. In another instance, a participant was hospitalized for pneumonia, although there was no record of the IRB being notified.

(http://www.fdanews.com/ddl/33_21/)

KEYWORDS FDAnews Device Daily Bulletin

Upcoming Events

  • 15Apr

    Five Telltale Signs You’re Ready for an Electronic TMF System

  • 21Apr

    CDER’s Most Significant Guidance Priorities for 2021: Biosimilars/Biologics, Generics/Exclusivity, Real-World Evidence, Drug Development and Digital Health

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

  • 06May

    The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • CE mark

    Roche Receives CE Mark for Elecsys Cancer Test

  • team up

    Biogen and Bio-Thera Solutions Partner Over Actemra Biosimilar

  • FDA logo blue

    Former Indivor Executive Seeks FDA Hearing to Avoid Debarment

  • FDA clears text

    FDA Clears Activ Surgical’s Imaging Module for ActivEdge Platform

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing